Volume 88, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Wider availability of the live, attenuated SA 14-14-2 Japanese encephalitis (JE) vaccine has facilitated introduction or expansion of immunization programs in many countries. However, information on their impact is limited. In 2006, Nepal launched a JE immunization program, and by 2009, mass campaigns had been implemented in 23 districts. To describe the impact, we analyzed surveillance data from 2004 to 2009 on laboratory-confirmed JE and clinical acute encephalitis syndrome (AES) cases. The post-campaign JE incidence rate of 1.3 per 100,000 population was 72% lower than expected if no campaigns had occurred, and an estimated 891 JE cases were prevented. In addition, AES incidence was 58% lower, with an estimated 2,787 AES cases prevented, suggesting that three times as many disease cases may have been prevented than indicated by the laboratory-confirmed JE cases alone. These results provide useful information on preventable JE disease burden and the potential value of JE immunization programs.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Fischer M, Lindsey N, Staples JE, Hills S, , 2010. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 59: 127. [Google Scholar]
  2. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS, , 2011. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 89: 766774.[Crossref] [Google Scholar]
  3. World Health Organization, 2005. Global Advisory Committee on Vaccine Safety, 9–10 June 2005. Wkly Epidemiol Rec 80: 242243. [Google Scholar]
  4. Liu ZL, Hennessy S, Strom BL, Tsai TF, Wan CM, Tang SC, Xiang CF, Bilker WB, Pan XP, Yao YJ, Xu ZW, Halstead SB, , 1997. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis 176: 13661369.[Crossref] [Google Scholar]
  5. Yaïch M, , 2009. Investing in vaccines for developing countries: how public-private partnerships can confront neglected diseases. Hum Vaccin 5: 368369.[Crossref] [Google Scholar]
  6. Kumar R, Tripathi P, Rizvi A, , 2009. Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N Engl J Med 360: 14651466.[Crossref] [Google Scholar]
  7. Tandan JB, Ohrr H, Sohn YM, Yoksan S, Ji M, Nam CM, Halstead SB, , 2007. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 25: 50415045.[Crossref] [Google Scholar]
  8. Henderson A, Leake CJ, Burke DS, , 1983. Japanese encephalitis in Nepal. Lancet 2: 359360. [Google Scholar]
  9. Joshi DD, , 1995. Current status of Japanese encephalitis in Nepal. Southeast Asian J Trop Med Public Health 26 (Suppl 3): 3440. [Google Scholar]
  10. Pant GR, , 2006. A serological survey of pigs, horses, and ducks in Nepal for evidence of infection with Japanese encephalitis virus. Ann N Y Acad Sci 1081: 124129.[Crossref] [Google Scholar]
  11. Bista MB, Shrestha JM, , 2005. Epidemiological situation of Japanese encephalitis in Nepal. J Nep Med Assoc 44: 5156. [Google Scholar]
  12. Zimmerman MD, Scott RM, Vaughn DW, Rajbhandari S, Nisalak A, Shrestha MP, , 1997. Short report: an outbreak of Japanese encephalitis in Kathmandu, Nepal. Am J Trop Med Hyg 57: 283284. [Google Scholar]
  13. Basnyat B, Zimmerman MD, Shrestha Y, Scott RM, Endy TP, , 2001. Persistent Japanese encephalitis in Kathmandu: the need for immunization. J Travel Med 8: 270271.[Crossref] [Google Scholar]
  14. Partridge J, Ghimire P, Sedai T, Bista MB, Banerjee M, , 2007. Endemic Japanese encephalitis in the Kathmandu valley, Nepal. Am J Trop Med Hyg 77: 11461149. [Google Scholar]
  15. Bhattachan A, Amatya S, Sedai TR, Upreti SR, Partridge J, , 2009. Japanese encephalitis in hill and mountain districts, Nepal. Emerg Infect Dis 15: 16911692.[Crossref] [Google Scholar]
  16. Wierzba TF, Ghimire P, Malla S, Banerjee MK, Shrestha S, Khanal B, Sedai TR, Gibbons RV, , 2008. Laboratory-based Japanese encephalitis surveillance in Nepal and the implications for a national immunization strategy. Am J Trop Med Hyg 78: 10021006. [Google Scholar]
  17. Burke DS, Nisalak A, , 1982. Detection of Japanese encephalitis virus immunoglobulin M antibodies in serum by antibody capture radioimmunoassay. J Clin Microbiol 15: 353361. [Google Scholar]
  18. World Health Organization, 2008. WHO-Recommended Standards for Surveillance of Selected Vaccine-Preventable Diseases. Report No: WHO/V&B/03.01. Available at: http://whqlibdoc.who.int/hq/2003/WHO_V&B_03.01.pdf. Accessed June 2, 2011. [Google Scholar]
  19. Andrus JK, Banerjee K, Hull BP, Smith JC, Mochny I, , 1997. Polio eradication in the World Health Organization South-East Asia Region by the year 2000: midway assessment of progress and future challenges. J Infect Dis 175 (Suppl 1): S89S96.[Crossref] [Google Scholar]
  20. World Health Organization Regional Office for South-East Asia, 2011. Malaria Situation in SEAR Countries: Nepal. Available at: http://www.searo.who.int/EN/Section10/Section21/Section340.htm. Accessed February 15, 2011. [Google Scholar]

Data & Media loading...

  • Received : 27 Mar 2012
  • Accepted : 09 Dec 2012
  • Published online : 06 Mar 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error